#Germany #Fresenius Medical Care #Bad Homburg #Charles Hugh-Jones #Franklin Maddux

Fresenius Medical Care Welcomes Charles Hugh-Jones

Fresenius Medical Care, renowned as the world's leading provider of products and services for individuals suffering from renal diseases, announces significant leadership changes within its management structure. Starting on January 1, 2026, Charles Hugh-Jones, MD, FRCP, will take on the role of Global Chief Medical Officer and will function as a member of the Management Board. This decision comes as part of a structured transition planning process, during which Franklin W. Maddux, MD, will retire from his position.

The appointment of Mr. Hugh-Jones positions Fresenius Medical Care for continued growth and innovation in the renal care sector. With a distinguished career that includes leadership roles at various biopharmaceutical companies, he formerly served as the CEO of Volastra Therapeutics, overseeing the transformation of the company from inception to a clinical-stage biotech focused on developing novel oncology treatments. His previous experience also includes serving as Chief Medical Officer at Allergan, later acquired by AbbVie, where he managed global medical operations and was instrumental in directing major product launches across diverse therapeutic areas. Additionally, he has held senior positions at Pfizer and Sanofi, advancing initiatives in chronic disease management, diabetes care, and cardiovascular treatments.

Mr. Hugh-Jones possesses an MD from Charing Cross and Westminster Medical School, University of London, and is a Fellow of the Royal College of Physicians in the UK. His extensive experience and robust understanding of the medical landscape are anticipated to bolster Fresenius Medical Care’s leadership in renal care.

Michael Sen, Chairman of the Supervisory Board, expressed his enthusiasm about Mr. Hugh-Jones's addition to the management team, stating, "We welcome Charles Hugh-Jones to the Management Board of Fresenius Medical Care. His expertise, experience, and recognition as a leader in the medical area will be key to fostering our leadership position in the renal space. We are delighted that we found such a capable successor."

He further acknowledged the substantial contributions made by Franklin W. Maddux, expressing gratitude for his dedication and wishing him well in his retirement. Helen Giza, CEO and Chair of the Management Board, emphasized the additional strength Mr. Hugh-Jones brings to the company, highlighting his diverse corporate experience and clinical leadership that will propel command over renal care while encouraging innovative approaches to future patient care.

Mr. Hugh-Jones remarked, "I am excited to join Fresenius Medical Care at this pivotal moment when the company is set to establish a new benchmark in kidney care in the U.S. through the introduction of the 5008X CAREsystem, alongside its enduring global leadership in kidney care. The Global Medical Office is pivotal in enhancing kidney care for patients and their families."

Fresenius Medical Care is dedicated to delivering unparalleled products and services to help the 4.2 million patients worldwide who regularly receive dialysis treatment. Operating through a network of 3,628 dialysis clinics, the company serves around 294,000 patients globally. Leading the way in innovation, Fresenius Medical Care continues to support the medical community with state-of-the-art dialysis machines and related products.

To learn more about Fresenius Medical Care, visit www.freseniusmedicalcare.com.

This news marks an important milestone for Fresenius Medical Care as it gears up for future developments and sets higher standards in the renal care field, ensuring excellent service and care for patients around the world.

Disclaimer

This announcement contains forward-looking statements that may encompass various risks and uncertainties affecting actual results. These could stem from changes in economic conditions, legal parameters, regulatory approvals, and clinical study outcomes, amongst others. Fresenius Medical Care does not undertake any responsibility to update forward-looking statements contained within this release.